Clinical trials: Neoplasms Recurrence
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This study is a single-arm Phase II trial designed to evaluate the efficacy and safety of Docetaxel, Nimotuzumab, and Pucotenlimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- PIONEER-HN (NCT07354984)
- Testing
- Drug Combination Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests.
- Trial name
- FACT (NCT02390947)
- Testing
- Famitinib
- Where
- 44 sites in China
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Sarcoma
Troglitazone in Treating Patients With Liposarcoma
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
- Trial name
- NCT00003058
- Testing
- troglitazone
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004858
- Testing
- B43-genistein immunoconjugate
- Where
- 3 sites in United States
- Sponsor
- Parker Hughes Cancer Center
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Ovarian Cancer, Platinum Resistance
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer…
- Trial name
- NCT07495384
- Testing
- CapsuleX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Breast Cancer
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as ABI-007(Nab-Paclitaxel((Nanoparticle Albumin Bound)-Paclitaxel)) and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Trial name
- NCT00110084
- Testing
- Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
- Where
- 201 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies the effect of re-irradiation with NBTXR3 in combination with pembrolizumab in treating patients with head and neck squamous cell cancer that cannot be removed by surgery (inoperable) and has come back…
- Trial name
- NCT04834349
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
This prospective observational study will enroll adults with gastric or gastroesophageal junction adenocarcinoma who achieve pathological complete response or major pathological response after neoadjuvant therapy and R0…
- Trial name
- NCT07799649
- Testing
- Tumor-Informed ctDNA-MRD Monitoring, Clinician-Selected Standard-of-Care Postoperative Treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent or Metastatic Colorectal Cancer
A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers
To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.
- Trial name
- NCT00155558
- Testing
- 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Rectal Cancer
Proton Therapy With Capecitabine for Rectal Cancer
The primary objective of the Phase I portion of this study is to evaluate the safety of a combination of capecitabine and proton therapy for patients with locally advanced or recurrent rectal cancer.
- Trial name
- NCT00503932
- Testing
- Proton Therapy, Capecitabine
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Oral Complications
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00008398
- Testing
- sargramostim, quality-of-life assessment, radiation therapy
- Where
- 236 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Relapsed or Refractory Advanced Cancer
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
The purpose of this study is to compare the pharmacokinetic profile of midazolam given alone and midazolam given after multiple oral doses of 40 mg ridaforolimus.
- Trial name
- NCT01071304
- Testing
- Midazolam, Ridaforolimus
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Cancer, Ovarian Cancer
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00022347
- Testing
- canfosfamide hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Glioblastoma
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious…
- Trial name
- NCT05341947
- Testing
- Activated T cells
- Where
- United States
- Sponsor
- Jeremy Rudnick, M.D
Kidney Cancer, Metastatic Cancer
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
This phase II trial is studying how well sorafenib works in treating patients with kidney cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth…
- Trial name
- NCT00301847
- Testing
- sorafenib tosylate
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cervical Cancer
Hydralazine Valproate for Cervical Cancer
The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved.
- Trial name
- NCT00532818
- Testing
- Hydralazine and magnesium valproate
- Where
- Mexico
- Volunteers
- 143 people
- Sponsor
- National Institute of Cancerología
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma (Skin)
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00090896
- Testing
- maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.